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Abstract
Plasmodium vivax is a major cause of febrile illness in endemic areas of Asia, Central and South America, and the
horn of Africa. Plasmodium vivax infections are characterized by relapses of malaria arising from persistent liver
stages of the parasite (hypnozoites) which can be prevented only by 8-aminoquinoline anti-malarials. Tropical P.
vivax relapses at three week intervals if rapidly eliminated anti-malarials are given for treatment, whereas in
temperate regions and parts of the sub-tropics P. vivax infections are characterized either by a long incubation or a
long-latency period between illness and relapse - in both cases approximating 8-10 months. The epidemiology of
the different relapse phenotypes has not been defined adequately despite obvious relevance to malaria control
and elimination. The number of sporozoites inoculated by the anopheline mosquito is an important determinant
of both the timing and the number of relapses. The intervals between relapses display a remarkable periodicity
which has not been explained. Evidence is presented that the proportion of patients who have successive relapses
is relatively constant and that the factor which activates hypnozoites and leads to regular interval relapse in vivax
malaria is the systemic febrile illness itself. It is proposed that in endemic areas a large proportion of the
population harbours latent hypnozoites which can be activated by a systemic illness such as vivax or falciparum
malaria. This explains the high rates of vivax following falciparum malaria, the high proportion of heterologous
genotypes in relapses, the higher rates of relapse in people living in endemic areas compared with artificial
infection studies, and, by facilitating recombination between different genotypes, contributes to P. vivax genetic
diversity particularly in low transmission settings. Long-latency P. vivax phenotypes may be more widespread and
more prevalent than currently thought. These observations have important implications for the assessment of
radical treatment efficacy and for malaria control and elimination.
Introduction
In endemic areas of Asia, Oceania, Central and South
America, and in the horn of Africa Plasmodium vivax
malaria is a major cause of morbidity. It is an important
contributor to early pregnancy loss and reduced birth
weight which increases mortality in infancy [1,2]. Plas-
modium vivax is a sophisticated and resilient malaria
parasite which was once prevalent over much of the
inhabited world. It has receded from North America,
Europe and Russia, but in the tropics vivax malaria
remains a major cause of childhood illness. In most
endemic areas, P. vivax cohabits with Plasmodium falci-
parum. Mixed infections with the two species are com-
mon. P. vivax is more difficult to control and eliminate
than P. falciparum because of its tendency to relapse
after resolution of the primary infection. In endemic
areas relapse of vivax malaria is a major cause of malaria
in young children, and an important source of malaria
transmission. Relapse also occurs in Plasmodium ovale
infections and in several of the simian malarias, notably
Plasmodium cynomolgi, which has often been used as an
animal model of vivax malaria. The factors which con-
trol relapse and determine their remarkable periodicity
are not known.
History
The history of clinical research on vivax malaria con-
tains a wealth of valuable information that is not widely
known or recognised. Most studies were conducted over
fifty years ago and are not readily accessible to the mod-
ern reader. Indeed more may have been forgotten than
has been learned about vivax malaria in recent years.
The tendency of malaria infections to recur was well
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specific treatment (Cinchona bark) was available for
agues (although for most of those infected it was unaf-
fordable). This treatment was often followed by frequent
relapses of the periodic fever, and so opinions differed
widely on its efficacy. Following Laveran’sd i s c o v e r yo f
the blood parasite that caused malaria in 1880 [3],
understanding of malaria epidemiology, pathology, and
treatment was placed on a rational basis. In 1885, Golgi
in Pavia distinguished the parasites responsible for ter-
tian and quartan fevers [4]. In 1890, P. vivax was identi-
fied as a separate species by Grassi and Feletti [5],
although debate continued into the early 1920s as to
whether there were indeed separate human malaria spe-
cies, or just one single polymorphic species [6]. Studies
of the time often tended to consider the responses of
the benign (vivax) and malignant (falciparum) tertian
malarias together. The Dutch physician Pel is generally
credited with the first postulation of an exoerythrocytic
stage of malaria in 1886 [7]. In 1897, the American phy-
sician WS Thayer gave a very clear description of a
long-latency relapse of malaria 21 months after the
initial attack in a physician who had probably not been
re-exposed between the two events [8]. Thayer and
Bignami (in Italy) [9] both surmised that relapses of
malaria resulted from a “spore” deposited in the internal
viscera which remained inert “only to be set free as a
result of some insult, the nature of which is still not
appreciable to us” [8]. Self-experimentation then pro-
vided remarkably accurate descriptions of long latencies
in vivax malaria. In 1900 in London Sir Patrick Manson
was investigating the mosquito transmission theory pro-
posed by his protégé Ronald Ross. Upon request
Bignami and Bastianelli kindly provided him with P.
vivax infected anopheline mosquitoes that had been fed
on malaria patients in the Ospedale Spirito Santo in
Rome. The mosquitoes were taken to the British
Embassy in Rome, and thereafter by the “Indian mail”,
and duly arrived in London 48 hours later. His son
Patrick Thorburn Manson, and George Warren (a
laboratory technician) both volunteered to be bitten.
Acute attacks of malaria followed after a two-week incu-
bation period, in September 1900. These were treated
successfully with quinine [10]. On June 1st the following
year, after a latent period of nine months, the younger
Manson experienced a sudden onset of rigors. Relapse
of his vivax malaria was confirmed by microscopy [11].
Meanwhile in India, at the end of 1900, Major CF
Fearnside infected himself with mosquitoes which had
fed on vivax malaria patients in the Madras jail. His pri-
mary attack of malaria began on January 14th, he suf-
fered a relapse on March 11 1901, and a second relapse
followed on November 11th apparently without the pos-
sibility of interim reinfection [12]. These precise
observations describing latencies of some eight to nine
months were complemented by Korteweg’s detailed and
painstaking prospective epidemiological observations
over more than two decades in the village of Wormev-
eer in The Netherlands. Celli had long surmised that
the spring wave of benign tertian (P. vivax) malaria in
Northern Italy resulted from relapse [13,14] but it was
Korteweg who provided convincing evidence that the
vivax malaria which emerged in the early summer had
been acquired in the autumn of the previous year
[15-19] (Figure 1). The considerable vivax malaria
experience of the First World War (in the Balkans,
Mesopotamia, and the Jordan valley), the secondary
cases in England which followed the year after the
return of infected soldiers, studies in American soldiers
serving in Panama and the Philippines, studies in British
soldiers serving in India, studies in Japanese soldiers
w h oh a di n v a d e dC h i n a ,a n dfurther epidemiological
observations and individual case reports in Europe and
the United States all pointed to a disease which could
relapse within two months of stopping quinine treat-
ment, but also tended to relapse some eight to ten
months later (Figure 2). Until the 1920s it was common
to recommend an eight-week course of quinine treat-
ment for malaria [20]. Despite this protracted treatment
relapses were common, but whether these resulted from
persistence of the blood stage infection (i.e. recrudes-
cence), or derived from a latent tissue stage was
unresolved.
Early observations on relapse
In 1913, Bignami proposed that relapses of malaria all
derived from persistence of small numbers of parasites
in the blood [21]. Although this theory explained the
late recurrences of Plasmodium malariae infections in
man, it did not explain several features of P. vivax and
P. ovale infections. A much clearer understanding of
relapse in P. vivax malaria was to come from Julius
Wagner-Jauregg’s discovery that malaria could cure neu-
rosyphilis. Between the 1920s and the 1950s thousands
of patients confined in mental hospitals with neurosy-
philis were treated with malaria (malaria therapy). Gen-
eral paralysis of the insane was then a uniformly lethal
condition, and at least half the malaria therapy treated
patents were improved and over one fifth were cured. It
was a remarkable period, unique in the history of medi-
cine, when, as Henry Dale put it, “Man was the experi-
mental animal”. The majority of the malaria therapy
experience was with a relatively small number of para-
site “strains” transmitted either by blood passage, or
more usually by the bites of several infected anopheline
mosquitoes. On the 8th September 1922 Professor War-
rington Yorke and JWS MacFie inoculated blood from a
patient with simple tertian malaria (P. vivax), which had
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at the Whittingham Mental Hospital near Liverpool
[22,23]. This “strain” was then used to infect multiple
patients initially by blood passage, and later by mosquito
transmitted infections. It soon became apparent that
recurrences of P. vivax (and P.ovale) malaria followed a
different temporal pattern to those of P. falciparum
[24-26]. Recurrences of vivax malaria commonly
occurred many months after apparently successful treat-
ment of the primary infection. Furthermore whereas
recurrence in blood transmitted vivax malaria could be
prevented by curing the blood stage infection, recur-
rence in mosquito transmitted vivax malaria could not
be [17,22-24]. This pointed to an exoerythrocytic stage
of malaria, but its anatomical location remained elusive.
The Dutch malariologists were able to show that their
indigenous P. vivax could have a short incubation per-
iod if patients were bitten by a large number of infected
mosquitoes, but, in a further example of courageous
self-experimentation, they proved that bites by one or
two infected mosquito were followed by vivax malaria 8
to 9 months later [26,27] (Figure 3). The Northern Eur-
opean and Russian “strains” of P. vivax therefore proved
unsatisfactory for malaria therapy because blood passage
was required to ensure an acute illness within weeks
[17,20,22-29] whereas mosquito infection, even with
multiple infected anophelines, often failed to produce an
early febrile illness. Importantly it was also noted in The
Netherlands that relapse rates in naturally acquired
infections were higher than with mosquito-transmitted
malaria therapy with local “strains” [17]. The most
widely used parasite used for malaria therapy in Europe
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Figure 1 Long-latency P. vivax in the Netherlands; The mean monthly number of malaria cases in the village of Wormerveer, The
Netherlands, recorded by Korteweg from 1902 to 1923 (black line) [15-17,19]. Swellengrebel et al showed that malaria transmission usually
occurred between the first week of August and the end of October [16]. From this it can be deduced that the initial wave of malaria cases
derived from inoculations the previous year (pink curve) and, by subtraction, that this was followed by relapses and primary cases with a short
incubation period in the late summer and autumn (blue curve) [19].
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seaman whose last port of call had been Madagascar
[8,21]. The “Madagascar” strain of P. vivax was exten-
sively investigated in England by James and later in sev-
eral European centres (Figure 2). It reliably produced an
acute infection with high fevers, sometimes relapsed
again within a few weeks, and then relapsed again
approximately eight months later. With serial passage
through man and mosquito the Madagascar strain
apparently became even more virulent (Figure 4) [30].
James’ terminology, which was adopted by several
others, was different to that used today. A recurrence
of malaria (any species) before eight weeks was termed
a recrudescence, recurrence from 8-24 weeks was
termed relapse, and return of malaria after 24 weeks
was called a recurrence. The pattern observed by
James in England, Swellengrebel in The Netherlands,
and Ciuca in Romania with the Madagascar strain of
P. vivax was very similar to patterns of the St Elizabeth
and McCoy strains, of indigenous origin, used for
malaria therapy in the United States [27-38]. These
strains were all chosen because of their suitability for
m a l a r i at h e r a p y ,s ot h e yp r o b a b l yr e p r e s e n t e dt h e
upper end of the spectrum of abilities to produce early
infection and relapse. The European studies, investiga-
tions in India by Sinton and colleagues, and in Florida
28weeks
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Figure 2 The temporal pattern of illness recurrence in patients with neurosyphilis artificially infected for malaria therapy with
Plasmodium falciparum (87 patients) and the “Madagascar” strain of P. vivax (105 patients) studied by SP James and colleagues at the
Horton Hospital, Epsom, England [24-26]between 1925 and 1930. The vivax relapses had a bimodal pattern with the majority having a long
latent period (mode 28 weeks) before the relapse.
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few weeks while others had only a primary infection,
and then exhibited the long-latency seen with the
Madagascar and St Elizabeth strains [24-30]. The dis-
tinction was often unclear as characterization of
latency required reliable long-term follow-up, and the
development of immunity with a febrile illness of
many weeks duration became a significant confounder.
As the object of malaria therapy was a prolonged high
fever, the consequent long illness obscured early
relapses. These single isolate (presumably single or
highly related genotype) infections eventually resulted
in solid immunity such that after several episodes of
protracted fever reinfection with the same isolate was
not possible [25-31,34,37]. This acquired immunity
suppressed later homologous relapses. Importantly for
our current understanding of P. vivax epidemiology
asymptomatic parasitaemia (and gametocytaemia)
tended to persist for weeks as disease controlling
immunity was acquired. Boyd and Kitchen, who stu-
died the McCoy strain in Florida extensively, noted
that relapse did not follow infections which had termi-
nated spontaneously (indicating an effective immune
response) or infections in which the primary illness
lasted for ≥ 48 days [31,34,37] (Figure 5). By contrast
all agreed that if prompt anti-malarial treatment was
Figure 3 Combined results of the preliminary mosquito infection studies of James and Shute in the Horton Hospital, Epsom, England
and the self experimentation of Shüffner, Korteweg, Swellengrebel-de Graaf, Swellengrebel, de Buck and de Moor in The Netherlands
as illustrated by Shüffner et al [27]. This confirmed the 8 to 9 month interval from being bitten by one or two infected anopheline
mosquitoes and developing vivax malaria
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Page 5 of 35Figure 4 The family history between May 1925 and May 1933 of the “Madagascar strain” of Plasmodium vivax as used in malaria
therapy at the Horton hospital [30]. The number within the circles refers to the number of patients infected with the “Madagascar strain” at
each time and the number over the lines refers to the batch number of the infected mosquitoes. Overall 24,361 mosquitoes and 1739 patients
were infected.
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relapses of vivax malaria were common.
During the malaria therapy experience it became clear
that both the incubation period and the number of
relapses were determined by the numbers of sporozoites
inoculated [25-28,38]. The Dutch had shown first [27],
and others later confirmed, that low sporozoite inocula
often resulted in an extended incubation period of 7-10
months. The more sporozoites that were inoculated, the
more likely was an early infection (incubation period
two weeks), and the more relapses that followed - pro-
vided that prompt anti-malarial treatment (quinine) was
given each time. Later clinical and experimental studies,
reported after the Second World War, were to confirm
these observations. In order to ensure that there was a
short incubation period preceding the malaria illness
malaria therapy infections were produced typically by
the bites of 5-10 infected mosquitoes, and either no
treatment or partial suppressive treatment was given.
Previous theories that seasonal influences were impor-
tant determinants of relapse were largely rejected as the
intervals from primary illness to relapse in neurosyphilis
patients were generally similar whichever month the
infection started [22-26].
Between the 1920s to the 1940s the long-latency infec-
t i o nw a sr e g a r d e da st h e“usual” P. vivax phenotype.
Throughout the endemic areas of Europe vivax malaria
peaked in the late spring and early summer (largely
from inoculations the previous year) [20,25]. In southern
Europe there was often a bimodal pattern with a late
summer peak of falciparum malaria [19]. The epidemio-
logical studies of malaria epidemics in Sind (now Paki-
stan) and Ceylon (Sri Lanka) followed a similar pattern
[19,25,39]. This suggested that long-latency P. vivax was
also responsible for the peak of vivax malaria cases
which occurred the year after the falciparum malaria
epidemics in these two tropical areas (although other
interpretations are also possible). During the Second
World War observations on Allied soldiers fighting in
North Africa, Italy, the Caucasus, and Greece, and
further observations in Japanese occupation forces in
China, all pointed clearly to long-latency P. vivax with
similar illness patterns to the Madagascar and St Eliza-
beth strains [40-45]. In contrast the soldiers on both
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Figure 5 Boyd’s 10 year experience with mosquito transmitted P. vivax malaria therapy in 375 patients studied at the Florida State
Hospital [93]. Most infections were with the McCoy strain, and some were with other local “strains” which he considered to behave similarly.
Infections which were allowed to continue until self termination did not relapse subsequently [31]. The median interval to relapse was
approximately 9 months. Inset is the study of Coatney et al [71] describing 403 mosquito transmitted infections with the St Elizabeth strain of P.
vivax.
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campaigns encountered vivax malaria with a very differ-
ent relapse pattern. Relapses were frequent and the
relapse rate was very high -in some companies all sol-
diers were infected and all relapsed. Infections occurred
at three week intervals if quinine was given, and seven
week intervals following mepacrine treatment [42-49].
Multiple relapses were very common and there was no
evidence of long latency. The “type strain” for this tropi-
cal frequent relapse P. vivax phenotype was the “Ches-
son strain” isolated from a soldier of that name who had
acquired the infection in New Guinea [50-52]. In volun-
teers infected with the Chesson strain 80% of relapses
occurred within 30 days of initial treatment with
quinine.
Discovery of the liver stages
In 1902, three years before his death, the eminent proto-
zoologist Fritz Schaudinn reported that he had observed
direct infection of erythrocytes by sporozoites [53].
There was therefore no need to postulate a tissue stage
of malaria. By the 1930s this theory was largely discre-
dited as others had tried and failed to reproduce the
observations, and by then tissue stages of bird malarias
had been demonstrated unequivocally. The existence of
a tissue stage of the malaria life cycle in humans was
considered sufficiently likely that the Malaria Commis-
sion of the League of Nations in 1933 suggested that the
sporozoite in human malaria went on to divide in cells
of the endothelial system as did Haemoproteus in birds.
In 1937 James and Tate showed that the exoerythrocytic
development of Plasmodium.gallinaceum took place in
the brain capillaries of chickens [54]. After the Second
World War, Fairley’s brilliant work at the Cairns experi-
mental station showed that sporozoites were cleared
from the blood within one hour of mosquito feeding on
volunteers, and in the case of P. vivax, parasites only
returned to the blood one week later [55-57]. Several
researchers had noted earlier that in the latent or inter-
relapse period even transfusion of as much as 500 mL
blood could not transmit P. vivax to a volunteer recipi-
ent, whereas if P. falciparum recurred -it could always
be transmitted beforehand by blood transfusion. It was
clear then that there was a pre-erythrocytic tissue stage
which preceded the blood stage infection, and also that
subsequent relapses originated from an exoerythrocytic
stage - but where was it? SP James, the eminent British
malariologist, was so convinced that there must be an
exoerythrocytic stage in the primate malarias that he
told the young PCC Garnham to stay in East Africa
until he had found it -and so he did! In 1947, Garnham
identified the pre-erythrocytic development of Hepato-
cystis (then Plasmodium) kochi in the hepatocytes of
African monkeys [58]. Shortly afterwards in England
definitive studies by Shortt and Garnham identified the
site of pre-erythrocytic development in primate malarias
as the liver, first in P.cynomolgi infected Rhesus mon-
keys [59,60], and then in a heroic experiment with P.
vivax in a very heavily infected volunteer who under-
went open liver biopsy [61-63]. This classic work still
did not identify the persistent stage, although later pri-
mate work suggested that relapses might arise from
arrested development of hepatic pre-erythrocytic schi-
zonts [63,64]. Forty years later Krotoski, working with
Garnham and colleagues at Imperial College, finally
identified the dormant stages or “hypnozoites” of P.cyno-
molgi and P. vivax responsible for relapses in the liver
[65-69]. Although parasite bodies, which are probably
hypnozoites, have since been demonstrated in liver cell
cultures [70] remarkably little is known of their biology.
The term relapse is now used specifically to describe
recurrences of malaria deriv e df r o mp e r s i s t e n tl i v e r
stages of the parasite (hypnozoites) whereas recrudes-
cence refers to a recurrence of malaria derived from
persistence of the blood stage infection. The relapse
arises after the “awakening” of these hypnozoites and
the subsequent intrahepatic schizogony followed by
blood stage multiplication. The question remained
unanswered as to how the hypnozoites were woken, and
what determined their remarkable periodicity.
Phenotypic variation in P. vivax
Today there is a tendency to regard all P. vivax together
as a single homogenous species, but the human malaria
therapy and volunteer studies showed that there was
substantial phenotypic variation between Plasmodium
vivax “strains”. There has been corresponding taxo-
n o m i cd e b a t eo v e rh o wt h e s e“sub-species” should be
defined (Figure 6). Studies conducted over fifty years
ago indicated that incubation periods, numbers of mero-
zoites per blood schizont, antigenic relationships, intrin-
sic drug susceptibility, virulence, and relapse intervals all
differed between “strains”. At that time the Plasmodium
vivax with infection phenotypes similar to those of the
“Madagascar” and “St Elizabeth” strains which were pre-
valent in the United States and Southern Europe were
considered the “typical” P. vivax infections
[24,25,31,34,71]. A primary illness followed approxi-
mately two weeks after mosquito inoculation, and,
although relapse could follow some three weeks later,
there was often a 7 to 10 month interval before a subse-
quent relapse. Sometimes the latency could be as long
as one year, and there were well documented, but
apparently unusual, cases reported of latencies greater
than two years. Further north in the Netherlands,
Northern Germany, Scandinavia, Finland and Central
Russia the long incubation phenotypes were prevalent
(P. vivax hibernans) in which the primary infection
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[17-20,23,24,27-29,43,72-74]. It seemed that the propor-
tion of infections which had a short incubation period
(circa two weeks) declined steadily with increasing lati-
tude (and shorter summer mosquito breeding seasons).
In artificial infection studies latency was independent of
season [22-26,71]. In the past twenty years infections
with intermediate relapse characteristics have been
reported but not well described from sub-tropical areas,
although as will be explained later, there may be other
explanations for relapses which emerge two to eight
months after sporozoite inoculation.
There was one very important and puzzling feature of
the long-latency P. vivax infections which still requires
explanation in any theory which seeks to explain relapse
periodicities; once the relapse had occurred (after a
latency of 7-10 months) subsequent relapses would then
usually occur with intervals of approximately 3 to 4
weeks following quinine -or 6 to 8 weeks if chloroquine
was given for treatment [17,19,23,71-73] (Figure 7).
Thus after the long latent period the subsequent inter-
vals were similar to the incubation period in temperate
infections with early relapses, and the inter-relapse
intervals in the tropical frequent relapse “Chesson” phe-
notype vivax malaria [75]. In contrast infections from
some parts of Russia were documented which had a sec-
ond long-latency after the first relapse(s).
Following the Second World War artificial infection
studies were conducted in several locations to study dif-
ferent anti-malarial treatment regimens. The administra-
tion of an effective schizontocidal drug allowed better
definition of relapse periodicity than the malaria therapy
studies (where the objective had been to produce a sus-
tained high fever). In the more prevalent tropical strains
of P. vivax treated in soldiers fighting in the Indo-Bur-
mese and South-West Pacific campaigns in the Second
World War, the relapses were documented to occur at
intervals of 3 to 4 weeks (as in the Chesson strain)
[42-52,76]. These observations were similar to those in
the seminal chemotherapy studies of Sinton and
Figure 6 Diagram of the different P. vivax phenotypes and the usual patterns of primary illness and relapse (after Bray and Garnham
[69]). The thickness of the lines gives a rough approximation of proportions.
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1920s and 1930s [32,77,78]. Interest in the long-latency
phenotype revived during the early 1950s as P. vivax
malaria which had a long-latency was an important pro-
blem in soldiers fighting in the Korean war [79]. During
this period patients who had received very heavy inocu-
lations, typically soldiers from the Second World War,
would return to clinics for many years complaining of
recurrences of malaria. The long latencies and the long
relapse intervals in some infections and the multiple
relapses in others despite anti-malarial treatment gave
rise to the old saw that “you never got rid of malaria”.
Relapse intervals
Effects of sporozoite inoculum
For long-latency vivax malaria from Northern climes the
sporozoite dose determined the clinical phenotype
[27-29,38,71-73]. In long term observations of infections
with the St Elizabeth strain there was a clear bimodal
pattern in which a long pre-patent period (~300 days)
only occurred following smaller sporozoite inocula
(more reflective of natural infection) [71]. Similar obser-
vations were made with a North Korean strain used for
malaria therapy in a Moscow hospital from 1953 to
1968 [28]. When the inoculum of sporozoites was small
(10-100 sporozoites) the initial parasitaemic illness did
n o to c c u rf o rn i n eo r1 0m o n t h s ,o rl o n g e r .I f≥ 1000
sporozoites were inoculated illness occurred after a
“normal” incubation period of two weeks. By contrast
when increasing sporozoite doses of the tropical “Ches-
son” strain were inoculated the incubation period shor-
tened and there was no evidence for a long prepatent
period [75,80]. This, and a series of experimental inves-
tigations in chimpanzees [80,81], led Garnham to pro-
pose that the ratio of hypnozoites to immediately
developing forms in the Korean P. vivax strain was
999:1 compared with the Chesson strain where he esti-
mated the ratio as 50:50 [68,69]. (Figure 6) Several other
important observations were made in the artificial infec-
tion studies conducted in humans and experimental pri-
mates. It was noted that even with a single infected
mosquito bite some Chesson strain P. vivax infections
relapsed after intervals which were as long as a year
after a series of regular “short interval” relapses [75].
These terminal long intervals did not appear to have a
fixed periodicity (Figure 8).
Figure 7 Schematic diagram by Hankey et al [79]of relapse patterns following Korean vivax malaria (upper panel) and tropical
frequent relapse P. vivax (lower panel). Note the frequent relapse pattern after a long interval with Korean vivax malaria.
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son strain P. vivax in volunteers, and also P.cynomolgi
in Rhesus monkeys, were remarkably regular although
they gradually lengthened with each successive relapse
[51,52,75,82,83] (Figures 9 and 10). Two factors are
likely to have explained these gradually lengthening
intervals - numerical probabilities and immunity. The
simultaneous activation of several hypnozoites will
shorten the relapse interval because the interval is mea-
sured until the progeny of the most rapidly growing
parasites cause patent infection. For example if ten
genetically identical hypnozoites are activated the
relapse interval will in 91% of occasions be shorter than
if one hypnozoite is activated. This is because there is
natural phenotypic variation even amongst genetically
identical organisms and it is the progeny of the earliest
activated and most rapidly multiplying parasite that
become patent first. This is best illustrated in the studies
of Coatney et al with the long-latency St Elizabeth strain
[71]. The interval from inoculation to relapse (~9
months later) shortened with increasing inocula. Thus
the more hypnozoites that are activated the shorter is
the average interval between relapses (Figure 11). This
relationship is also clearly seen in Schmidt’ss t u d i e so f
P.cynomolgi in monkeys [82] (Figure 9). This is an
important consideration for concomitant activation of
hypnozoites with different genotypes in endemic areas
as will be discussed later. In natural settings multiple
genotypically distinct hypnozoites may be activated but,
on many occasions, only one or two genotypes will be
397days
Figure 8 Relapse patterns in volunteers in the USA who were infected by a single mosquito bite with the Chesson strain of P. vivax
studied by Coatney et al [75]. Some were rechallenged as indicated.
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Page 11 of 35detected subsequently at clinical relapse. The other hyp-
nozoites’ progeny may reach patency later, or asexual
g r o w t hm a yb es u p p r e s s e db yf e v e r ,i l l n e s s ,i m m u n e
response, and treatment such that they never reach
patency.
Effects of immunity
The second factor accounting for lengthening inter-
relapse intervals in artificial infections was the acquisi-
tion of blood stage immunity against the single infecting
genotype. In the studies of the St Elizabeth strain there
was clear evidence that late relapses were attenuated if
there was an early infection, but this did not affect the
interval to latency (Figure 11), whereas with increasing
size of sporozoite inoculum there was a corresponding
shortening of the interval. These observations suggest
that inoculum size is more important than immunity in
determining the duration of latency or the inter relapse
interval - at least for the first relapses with genetically
homologous parasites [71]. In Schmidt’s primate studies
(Figure 9) the lengthening of inter-relapse intervals was
Figure 9 Relapse patterns of P.cynomolgi infections in Rhesus monkeys studied by Schmidt [82]. The infections were induced with
different numbers of injected sporozoites as indicated and treated repetitively with chloroquine. Monkeys in groups A, B, C, and D were
inoculated, respectively, with 5 × 10
6,5×1 0
4,5×1 0
2 and 5 sporozoites. Some monkeys were rechallenged and some were finally given radical
treatment with primaquine in addition.
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[51,52,71,82,83] and increasing inter-relapse intervals
were seen only after 12 or so relapses [82], although in
these experiments the inocula were very large, and all
animals received chloroquine treatment which was
given early (on the second day of patency). Schmidt
also observed in the Rhesus monkeys infected with P.
cynomolgi [82], as Coatney had done earlier in volun-
teers infected with the Chesson strain of P. vivax [75],
that occasionally a very long interval would follow a
series of short intervals. Thus the steadily increasing
intervals between the homologous strain relapses result
from both the “running out of hypnozoites” with suc-
cessive relapses, which results in reversion to the mean
intervals associated with single hypnozoite activation,
together with slower asexual growth rates resulting
from the acquisition of asexual stage immunity. Blood
stage immunity against homologous strains of P. vivax,
which persists for many months, was a consistent
observation in malaria therapy and challenge studies
[34,84]. Boyd noted that if the initial infection was
allowed to run its natural course, then relapse did not
occur and reinfection with the homologous strain was
not possible [34].
Effects of drugs
Since the introduction of mepacrine (atebrine, quina-
crine) in 1932, a drug which has a terminal elimination
half-life of over one month, it was observed that early
relapses were delayed by approximately thirty days com-
pared with quinine treatment (i.e. from three to seven
weeks) [40,47]. Later chloroquine, which also has a term-
inal half-life of over one month, but a different elimina-
tion profile to mepacrine, was found to delay early
relapse appearance by two to six weeks [40,47]. Larger
doses of the anti-malarials resulted in longer intervals to
relapse consistent with a concentration-dependent slow-
ing of asexual growth rates. Slowly eliminated anti-malar-
ials delayed the onset of P. vivax relapse, and
consequently reduced their frequency, but importantly
these drugs did not appear to reduce the overall number
of relapses experienced [47] (Figure 12). Only the 8-ami-
noquinolines reduced or prevented relapses. The relapse
preventing properties of these drugs, and their synergistic
action with quinine, were demonstrated within years of
their introduction in the mid 1920s [85-87].
Two other key observations were made during this
early era of malaria therapy and drug evaluation which
were not satisfactorily explained until decades later. It
was noted that haemolytic reactions occurred sporadi-
cally with plasmoquine in patients of Asian, African or
South European descent, but were uncommon in Cauca-
sians originating further north [88]. This was explained
later by the epidemiology of glucose-6-phosphate dehy-
drogenase deficiency. In the Southern United States it
proved difficult of impossible to infect patents or volun-
teers of West African descent with P. vivax [34]. This
was later shown to reflect the absence of the Duffy
blood group receptor for P. vivax invasion of erythro-
cytes in this population.
Contrasting artificial with natural infections
Artificial infections provided invaluable information but
they differed from natural infections in several impor-
tant respects [89]. The infections were in non-immune
adults whereas the burden of vivax disease in endemic
areas was in children. Adults in the malaria endemic
areas have usually developed significant immunity to a
broad range of local parasites which controls symptoms
and reduces parasite densities. The artificial infections
in the majority of volunteer studies and in malaria ther-
apy followed the bites of 5-10 infected anopheline mos-
quitoes selected for maximal infectivity based on
salivary gland sporozoite loads in sibling mosquitoes.
The timing of inoculation in malaria therapy and experi-
mental studies to coincide with maximum infectivity
contrasts with the natural setting where anopheline
mosquitoes display a wide range of infectivities depend-
ing on sporozoite age and other factors. The inocula in
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Figure 10 Lengthening intervals between sequential relapses
in individual volunteers who were infected with the Chesson
strain of P. vivax, each of whom was treated with quinine for
16 days [83]. Diamonds represent median values.
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This resulted in reliable infections but did not bring out
the important stochastic component of P. vivax epide-
miology resulting from low sporozoite inocula in areas
of low seasonal transmission. Median sporozoite inocula
in natural infections are estimated to be less than 10
sporozoites [90-92]. If Garnham’s estimates (50:50 ratio
of immediately developing parasites to hypnozoites) are
correct this corresponds to a median of 5 hypnozoites
in tropical P. vivax infections. The “strains” of P. vivax
used in malaria therapy were likely to have been of a
single (albeit evolving) genotype or very closely related
interbreeding genotypes which were passaged through a
very large number of patients over many years. Even if
these infections originated as a mixed genotype infec-
tions in the donor patient it is likely that with multiple
passage in malaria therapy the “strains” became purified
through successive interbreeding to a very closely
related group of genotypes. In contrast multiple unre-
lated genotype infections are common in natural
infections.
The malaria therapy patients usually had neurosyphilis
and were often very frail. Overall the mortality asso-
ciated with P. vivax malaria therapy was approximately
7% (and was 10% with P.malariae infections -generally
regarded as the mildest human malaria) [17]. This high
mortality reflects the underlying condition, although it
was undoubtedly contributed to by the infection as well.
The objective of treatment in natural infections is cure,
but in malaria therapy quinine was used to “damp
down” the more severe infections, not to eliminate
them. Reinfection with a different genotype was usual in
endemic areas but in malaria therapy this was underta-
ken only occasionally if the first infection was insuffi-
cient, and in volunteer studies was performed to
demonstrate the “strain specificity” of the immune
response.
The proportion of infections which relapse
The proportion of P. vivax infections which relapse is
often thought of as an intrinsic property of the malaria
parasites which varies considerably by geographic
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Figure 11 In infections of volunteers with the St Elizabeth strain of P. vivax [71], there was no evident relationship between the
occurrence or duration of the primary illness and the long-latency interval before illness (left panel), whereas there was an inverse
relationship between sporozoite inocula (assessed semi-quantitatively from sporozoite numbers in the salivary glands and number of
infectious bites) and the latency interval.
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Page 14 of 35region. Tropical “strains” relapsed more than temperate
“strains”. But the relapse proportion is also clearly a
function of the sporozoite inoculum and immunity (if
any). As described earlier if artificial sporozoite induced
infections were allowed to continue for weeks until self-
termination the relapse did not usually occur and reino-
culation was usually unsuccessful [34,84,93] (Figure 5).
In this setting the probability of relapse with a presumed
single genotype depended on the duration of preceding
illness.
In total, the treatment responses in over 87,000
patients with acute vivax malaria have been reported in
the available medical literature in English (> 300 publi-
cations) of whom ~17,000 relapsed (Figure 13 and Fig-
u r e1 4 ) .T h i se x p e r i e n c eo faw i d ev a r i e t yo fa n t i -
malarial treatment regimens, is heavily biased to adults
and military reports. Two-thirds of the reports are over
fifty years old. The reported relapse rates varied from 0
to 100%! Many relapse rates are likely to have been
underestimated as follow-up periods, particularly in
recent studies, were often two months or less, and in
the majority of studies radical treatments were being
evaluated. On the other hand studies conducted in
endemic areas could not exclude reinfection. The
relapse rate was very high in soldiers who were generally
non-immune and presumably experienced intense expo-
sure. In the Second World War 70 to 80% of soldiers
fighting in the South Pacific had relapses (and in many
units all soldiers had relapses). In Hill and Amatuzio’s
series of 222 patients, 9% had 10 or more relapses [76]
(Figure 15). Relapses were estimated to account for
about half of all vivax malaria hospitalizations in the
Second World War [94]. Once chemoprophylaxis was
enforced in soldiers it became clear that almost all
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Figure 12 Cumulative proportions of relapses in soldiers with vivax malaria acquired in the Pacific and treated subsequently with
different anti-malarial drug regimens in Chicago. Regimens were quinine; 2 g/day for 14 days (N = 75), mepacrine 0.4 g/day for 7 days (N =
69), chloroquine 1.5 - 2 g/day for 4-7 days (N = 82), and quinine 2 g/day and plasmoquine 60 mg/day for 14 days (N = 72) [47].
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the mepacrine (quinacrine, atebrine) was stopped P.
vivax relapses started to occur [47].
Without radical treatment the proportion of patients
who experience one relapse, the proportion of these
patients who have a second relapse, and the proportion
of these who have a third and so on, is constant (Table
1). This appears to obtain in each different epidemiolo-
gical or experimental setting [23,24,28,29,41,42,47-49,51,
52,72,76,79,85]. In other words the relationship between
the numbers of patients who experience one or more,
two or more, three or more etc relapses is exponential.
Thus if “x” is the fraction of patients experiencing one or
more relapses, then the fraction experiencing “n” or more
relapses is approximately x
n
A plot of the logarithm of the proportions versus num-
ber of relapses is, therefore, linear with slopes varying
depending on the geographical and epidemiological
setting (Figure 16). Thus, for areas with 50% relapse
rates approximately 6.25% of patients have four or more
relapses per incident symptomatic infection. This is
important when considering radical curative drug effi-
cacy as it provides an indication of the minimum bur-
den of hypnozoites (because each relapse must derive
from ≥ 1 hypnozoite) (text box on pharmacodynamics).
It follows that once symptomatic relapse rates exceed
50%, then relapse becomes the predominant cause of
vivax malaria illness.
Geographic distribution
Overall there was good evidence for the presence of the
long-latency “Madagascar” relapse phenotypes in Eur-
ope, Central Asia, Southern Russia, North Africa, the
horn of Africa, Madagascar, the Middle East, Afghani-
stan, Pakistan and Northern India, Central parts of
China, Korea, North and Central America (Figure 17).
Long incubation period P. vivax (”hibernans“)w a s
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Figure 13 P. vivax relapse rates without radical treatment in published studies conducted between 1920 and 2010.E a c hc i r c l e
represents one study arm. The horizontal scale represents the study location from West (United States) to East (Pacific). A very wide range of
treatments were used in a very diverse range of patient groups.
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Page 16 of 35prevalent in Northern Europe and more Northern parts
of Russia. Frequent relapse “strains” were reported in
parts of South America, India, South East Asia and
Oceania. It is highly likely that in those areas where
malaria has not been eradicated this geographic distribu-
tion of P. vivax phenotypes pertains today, although
there is very little contemporary information apart from
reports from South East Asia and the island of New
Guinea (which has much higher levels of malaria trans-
mission than most other P. vivax endemic areas of the
world). It is also evident that both phenotypes overlap
in geographic distributions (Figure 17). Where both are
present together it would be very easy for the long-
latency infections to go unrecognized, although the pre-
sence of a spring vivax malaria peak while vector densi-
ties are still low would be an epidemiological pointer
[19,20]. There has been very little recent interest in this
question despite its obvious importance. It is generally
thought, but is by no means certain, that the majority of
the global burden of vivax malaria today is the tropical
frequent relapse type (although interestingly the first P.
vivax to be sequenced fully was a long-latency pheno-
type from El Salvador-Sal 1) [95,96]. The greatest uncer-
tainty is the epidemiology of relapse phenotypes in the
Indian sub-continent, because India harbours the major-
ity of P. vivax in the world and clearly has both pheno-
types. This remarkable gap in our understanding of the
global epidemiology of vivax malaria seems to have gone
unrecognized outside the sub-continent.
Prospective studies from India over the past 25 years
have recorded relapse rates following chloroquine treat-
ment of between 8.6% (Orissa) and 8.9% (Madhya Pra-
desh) and 40.1% (Delhi) [97-99]. In Mumbai 19 out of
150 patients with vivax malaria and treated with chloro-
q u i n eo n l ya n dw h ow e r ef o l l o w e df o ro n ey e a rh a da
relapse (17 within six months) [99]. Reinfection was
considered unlikely. Higher rates were reported from
the Delhi area [98] where the authors concluded “Based
on the foregoing epidemiologic features, three distinct
relapse patterns were observed in the present study, and
Figure 14 P. vivax relapse rates following treatments which included 8-aminoquinolines (mainly plasmoquine or primaquine).
Otherwise as for Figure 13
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northern India is polymorphic. Group I is the tropical
or Chesson strain type of frequent relapsing P. vivax
with a short period of latency between the primary
attack and the first relapse, which is similar to other
Southeast Asian strains such as those from Thailand
and Vietnam. Group III is the temperate or St. Eliza-
beth-type strain that has a long period of latency
between the primary attack and the first relapse. Group
II is intermediate between these two types” [98]. This
intermediate group, if it exists, has not been well charac-
terized. The ratio of short to long-latency relapse phe-
notypes in Aligarh, Uttar Pradesh was estimated as 4:1
[100]. Overall relapse rates from India have been rela-
tively low by comparison with South-East Asia [97-107].
Data from travellers returning from the Indian sub-con-
tinent have suggested that long incubation-period P.
vivax may be common in the Punjab, and this is
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Figure 15 Proportions of P. vivax relapses in 222 US servicemen who had fought in the South Pacific in the Second World War [76].
Table 1 Relationship between the proportion of patients relapsing with vivax malaria and total number of relapses
experienced
Proportion of incident P. vivax infections followed by ≥1 relapse (%) Mean number of relapses per incident infection
90 8.3
80 4.0
70 2.3
60 1.5
50 1.0
40 0.67
30 0.43
20 0.25
10 0.11
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India, Pakistan and Afghanistan [108,109] and also the
early observations of Fearnside, Yorke, and MacFie with
artificial infections of Indian origin [12,22,23]. There are
few data on temporal patterns of relapse in travellers in
recent years, although studies in Eritrean immigrants to
Israel, Turkish immigrants to Germany, and US soldiers
returning from Somalia suggest the presence of long-
latency phenotypes in the countries of origin [110-112].
Most travellers receive radical treatment for vivax
malaria in temperate countries, which may be more
effective against the long incubation or long-latency
infections than against the tropical frequent relapse
phenotypes.
The tropical frequent relapse phenotype was docu-
mented by Sinton and colleagues in British soldiers sta-
tioned in India in the 1920s and 1930s, and was
observed in soldiers fighting in North-East India and
Burma, and in prisoners of war in Thailand [46]. More
recently Luxemburger et al studied 342 children with
acute vivax malaria treated with chloroquine on the
north-western border of Thailand in 1995 and 1996
[106]. Reappearance of P. vivax occurred in one patient
o nd a y2 1a n di n8b yd a y2 8 ,g i v i n ga2 8 - d a yc u r er a t e
of 97% [95% confidence interval (CI) 95-99%]. By day
63, the relapse/re-infection rate was 63% (95% CI 57-
69%). Most reappearances of parasitaemia (85%; 121/
143) were symptomatic. Silachamroon et al studied
adult patients in Thailand (infections from Burma, Thai-
land, or Cambodia) with acute vivax malaria who were
treated with either 5 days (N = 157) or 7 days (N = 159)
of artesunate monotherapy [107]. Relapse rates within
28 days were 52.2% and 47.8% respectively. The timing
of the relapses suggested that very few if any relapses
emerged from the liver before the eighth day after start-
ing anti-malarial treatment. In Papua Indonesia the
relapse rate estimated at six weeks following arte-
mether-lumefantrine treatment was 38% (the total num-
ber may well have been higher because of later
emerging relapses) [113]. In French Guiana the relapse
rate in children was 70% (nearly all relapses occurred
within three months) but both recrudescence and rein-
fection could not be excluded [114]. Although South
American P. vivax is generally regarded as “tropical fre-
quent relapsing” in phenotype, a recent report from Rio
de Janeiro that six of 80 travellers presenting with vivax
malaria (who had returned from the Amazon region and
not received chemoprophylaxis) had an incubation
LonglatencyP.vivax
FrequentrelapseP.vivax
Frequentrelapse+longlatencyP.vivax?
Figure 16 The proportions of patients experiencing successive P. vivax relapses taken from eight different clinical series: These were
US soldiers with vivax malaria acquired in the South Pacific (2 series) [49,76], German soldiers who acquired vivax malaria in Greece [41], US
soldiers with vivax malaria acquired in the Mediterranean area (two series)[45,47]and Italy[156], patients receiving malaria therapy with a local
“strain” in Moscow [28], British patients receiving malaria therapy with the Madagascar strain [24,25], patients receiving malaria therapy with the
McCoy strain in the United States [93], volunteers infected with the Chesson strain in the United States [75] and children followed prospectively
in an evaluation of an ineffective malaria vaccine (SPf66) in northwestern Thailand [157]. Inset shows proportions on a log scale and numbers of
patients studied.
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Page 19 of 35period of between three to 12 months, and another from
Brasilia describing long-latency in three patients, suggest
that long-latency forms may coexist with frequent
relapse phenotypes in Brazil [115,116].
The effects of age
In malaria endemic areas, such as the north-western
border of Thailand, the age profile of P. vivax malaria
suggests much more rapid acquisition of immunity than
for P. falciparum [117] (Figure 18). Entomological stu-
dies suggested similar transmission rates (at least in
terms of measured entomological inoculation rates) so it
is likely that relapse contributes to much of this differ-
ence. It also suggests that relapses are probably partially
suppressed in older patients. Thus both the proportion
of infections which relapse and the number of sympto-
matic relapses per mosquito sporozoite inoculation
decline with age. It is likely that immunity and therefore
age is a significant confounder in epidemiological assess-
ments based on passive case reporting in many P. vivax
endemic areas. In many areas adults are more likely to
present to malaria clinics than children. In India the
peak age of malaria presentation is often in young adults
(and often with a predominance of young males). Yet in
the indigenous population living in transmission areas a
significant degree of immunity should have been gained
(by both sexes) by early adulthood which reduces the
number of relapses. Usually in endemic areas it is chil-
dren who bear the brunt of malaria. This applies to
both falciparum and vivax malaria when malaria is
uncontrolled, but with increasing control falciparum
declines more rapidly than vivax, and their epidemiology
separates. The paucity of data from children may contri-
bute to the low apparent relapse rates reported from the
Indian sub-continent. It seems likely then that malaria
clinic data are not necessarily representative of disease
epidemiology in some endemic areas, and that studies of
children living in the endemic areas of the Indian sub-
continent might reveal higher relapse rates.
Drug effects on relapse
Before the Second World War most malaria infections
were treated with quinine. Early relapses of P. vivax
were observed to occur approximately three to four
weeks after starting quinine treatment. The 8-aminoqui-
noline plasmoquine (plasmochin, pamaquine) was evalu-
ated clinically shortly after its discovery in 1924 in
Germany. Sinton and colleagues in India soon provided
evidence that plasmoquine synergized with quinine in
the treatment of acute vivax malaria and also reduced
the rate of recurrence (mainly relapse) [85,86]. “Sinton’s
regimen” of one week’s quinine plus plasmoquine was
endorsed by the League of Nations and generally
replaced the two-month regimens previously in vogue
[16]. In the 1930s the newly introduced sulphonamides
were shown to have activity against malaria, but were
more effective against P. falciparum than P. vivax [47].
The discovery of mepacrine (quinacrine, atebrine) in
1932 and its subsequent introduction provided a sim-
pler, somewhat better tolerated, treatment although
there was a pharmacokinetic interaction with
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Figure 17 Approximate historical distribution of P. vivax
latency phenotypes. Areas where tropical “frequent relapse
phenotypes” are prevalent are shown in pink. Areas where both
frequent relapse and long-latency phenotypes have been reported
are shown in purple, and areas where long-latency phenotypes
were prevalent are shown in grey. Although both South America
and India are generally considered to harbour frequent relapse
phenotypes predominantly, there is evidence that long-latency
phenotypes are present in both areas (particularly across the North
of India), and without genotyping it may be difficult or impossible
to distinguish the two phenotypes within an endemic area (Figure
22).
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Figure 18 The epidemiology of vivax and falciparum malaria in
an area of low seasonal transmission on the Western border of
Thailand; age incidence profiles [106].
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Page 20 of 35plasmoquine which resulted in increased plasmoquine
concentrations and oxidative toxicity, and precluded
using the drugs simultaneously [118]. Mepacrine was
very slowly eliminated and extensively distributed [119].
It was an effective treatment of vivax malaria. Mepacrine
treatment markedly delayed the early relapse of tropical
P. vivax which, usually then presented six to eight
weeks after the primary infection rather than three
weeks later, as was usual following quinine. When
mepacrine was used as a prophylactic it suppressed
infections for at least one month after stopping the drug
[47,119,120]. Thereafter relapses followed soon after-
wards in tropical areas where frequent relapse “strains”
were prevalent, and many months later where long-
latency “strains” were prevalent.
Extended follow-up studies suggested that although
the relapses were delayed, they were not prevented [47]
(Figure 12). It was assumed that the slowly eliminated
treatment had suppressed the expansion of the blood
stage infection (post treatment prophylaxis). It was
unclear whether the relapse seen later was the first
relapse which had been suppressed for three or more
weeks, or whether the first relapse had been prevented
altogether and it was in fact the second relapse (but the
first clinical evidence of relapse) that became patent six
to eight weeks after starting initial treatment. Mepacrine
(atebrine, quinacrine) wa st h em a i nd r u gu s e db ya l l
sides in the Second World War. The British were more
willing to use plasmoquine than the US forces who dis-
continued its use during the war. They considered the
risk exceeded the benefit [121], possibly because reac-
tions were common in African-American soldiers (pre-
sumably G6PD deficient individuals who haemolysed).
R e l a p s eo fv i v a xm a l a r i aw a sam a j o rp r o b l e mi ns o l -
diers, and was well documented in all the tropical thea-
tres of war. Immediately after the Second World War
the enormous research effort to find new anti-malarial
drugs gave chloroquine (discovered in 1934 and initially
overlooked), proguanil, and new more effective and less
toxic 8-aminoquinolines. Chloroquine was clearly the
best anti-malarial yet to be discovered, but like quinine
and mepacrine, it acted only on the blood stage para-
sites. Proguanil, and later pyrimethamine, were both
shown to have pre-erythrocytic activity but not radical
curative activity. Furthermore resistance arose readily to
the antifol anti-malarials in P. vivax. Although plasmo-
quine was moderately effective it was relatively poorly
tolerated in the dose regimens necessary to prevent
relapse (radical cure) [83-88]. The more effective and
better tolerated 8-aminoquinolines pentaquine and then
primaquine were developed and evaluated between 1944
and 1955 [122-126]. Primaquine took over as the stan-
dard radical treatment of vivax malaria (except in the
USSR where the positional isomer quinocide was
preferred). The 8-aminoquinolines also have significant
blood stage activity against P. vivax (and Plasmodium
knowlesi) although resistance in the blood stage infec-
tion can be induced experimentally [127]. The widely
used chloroquine-primaquine regimen should therefore
be considered a combination treatment. The 8-amino-
quinoline development programme also uncovered the
reason why some patients of African or Asian origin
developed severe haemolysis, whereas Caucasian patients
originating from Northern Europe did not haemolyse
significantly. X-linked Glucose-6-phosphate dehydrogen-
ase (G6PD) deficiency was discovered as the most com-
mon genetic defect of humans [128,129]. The dose of
primaquine recommended globally was chosen largely as
a result of studies on the relatively drug-sensitive Kor-
ean P. vivax [125,126,130]. After a very high rate of
relapses was observed in US soldiers returning in 1950
from the Korean war (Figure 19), all soldiers were given
a radical curative regimen of 15 mg base/day for two
weeks during their return by sea [125]. This proved very
effective. The Chesson strain had been shown to be
more “resistant” to 8-aminoquinolines [124], but recom-
mendations for a higher dose of primaquine (adult dose:
22.5 mg base/day) were applied initially only in Oceania.
In hindsight there was no very good reason for this, and
it might have been better to recommend higher doses
for all frequent relapse parasites (i.e. in South-East
Asia). It remains possible that all temperate “strains” are
equally sensitive to primaquine, and all tropical strains
are equivalent but have higher burdens of hypnozoites
NumberofP.vivaxrelapses
Exposure
Figure 19 Numbers of US servicemen admitted to hospital in
the USA each week with vivax malaria following their return
from the Korean war. Exposure was predominantly in 1950.
Figures taken from the Office of the US Surgeon General.
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higher dose (i.e. 0.5 mg/base/kg for 14 days) (Table 2).
This highlights the need for better discrimination of the
tropical and temperate phenotypes and a better under-
standing of the epidemiology of relapse, and the phar-
macokinetic-pharmacodynamic basis of radical
treatment. One particular area of therapeutic relevance
is the question of synergy. Sinton’sw o r ki nI n d i ah a d
suggested that quinine and plasmoquine were synergistic
in the prevention of relapse in vivax malaria [85,86] and
studies during and after the Second World War [47]
provided further support for this notion. Ruhe et al
showed that concurrent quinine and pamaquine (plas-
moquine) was more effective in prevention of relapse
with the St Elizabeth strain than sequential administra-
tion [131]. In the 1950s, Alving and colleagues con-
ducted a formal interaction study which provided
evidence of marked synergy between both quinine and
chloroquine and primaquine [132]. The reason for this
synergy (i.e. was it pharmacokinetic or pharmacody-
namic?), and whether it extends to other quinolines or
related compounds has not been explored further.
The mid 1950s saw a decline in clinical research on
vivax malaria. Meanwhile most countries adopted the 15
mg base/day primaquine regimen usually given for 14
days. Five day regimens of primaquine (total adult dose
75 mg base) were recommended in the Indian subconti-
nent, although there was no evidence they were effective
[97-105,133]. Baird has recently pointed out that the
much improved tolerability of primaquine when taken
with food was not emphasized sufficiently at this time
and thus later dosage recommendations may have been
limited by perceived or observed poor tolerability [134].
In the recent reawakening of interest in malaria it has
been suggested that resistance to the radical curative
activity of primaquine has emerged [135] - but it is not
at all clear if there has been any significant change in
susceptibility. As noted earlier, because the tropical phe-
notype is usually associated with a greater number of
relapses than the temperate phenotype, then it requires
a greater proportional reduction in activatable hypno-
zoites to prevent all relapses. More clinical pharmacol-
ogy evidence on these important points is needed.
Vivax malaria following falciparum malaria
In July, 1921 Major JA Sinton VC was put in charge of
the Indian quinine and malaria inquiry under the newly
formed Central Malaria Bureau. Between March 1924
and July 1925 Sinton compared two different quinine
regimens in the treatment of falciparum malaria in Brit-
ish soldiers. These soldiers were followed for eight
weeks at Kasauli (above the level of malaria transmission
at an altitude of 6,000 feet in Himachal Pradesh). Of 76
soldiers completing follow-up 30 (39%) had subsequent
vivax malaria [77]. In East Asia and Oceania a similar
pattern pertains today. In East Asia a remarkably high
proportion (20-50%) of symptomatic infections with P.
falciparum are followed by an infection with P. vivax
[136-138]. In Ethiopia where early relapse rates in vivax
malaria are much lower, this proportion is also lower;
7% [139]. The intervals between the onset of treatment
for the acute P. falciparum infection and the subsequent
P. vivax infection are very similar to the intervals
between acute vivax malaria and the first relapse (Figure
20). As the treatments given for falciparum malaria are
highly effective, and therefore should be curative against
t h eb l o o ds t a g ei n f e c t i o n so fP. vivax, these recurrent
malaria infections are highly likely to be relapses.
Furthermore, as with relapses after vivax malaria, the
probability of vivax recurrence after falciparum malaria
is also age related [138]. Several lines of evidence
detailed below point to these vivax episodes being
relapses of latent hypnozoites acquired before the P. fal-
ciparum inoculation.
The periodicity of relapse
Various theories to explain the remarkable periodicity of
Plasmodium vivax infections have been proposed [140]
Table 2 Radical treatment pharmacodynamics; Quantitative considerations
Consider two groups of patients who represent two extremes
Without radical treatment group A has an 80% relapse rate (eg some soldiers who fought in the Pacific in the Second World War)
Without radical treatment group B has a 20% relapse rate (eg some soldiers who fought in the Korean War)
Assuming a fixed fractional proportion of relapses and no acquisition of immunity, then the total number of relapses/100 patients is
group A = 395, group B = 24.
These numbers represent the minimum number of viable activatable hypnozoites (VAH) i.e. there are 16 times more in group A compared to group
B. It is likely that the distribution of VAH is random among the patients and therefore conforms to a Poisson distribution.
If primaquine at a dose of 0.25 mg base/kg (15 mg adult dose) reduces the number of viable activatable hypnozoites (VAH) by 90%, and there is no
difference in susceptibility between the groups, and this effect is consistent across all patients then the post treatment number of VAH is
group A = 39 or 40 group B = 2 or 3.
Thus we would expect 13 to 20 times more relapses in group A compared to group B.
This hypothetical example simply points out that the apparent differences in primaquine “resistance” may reflect differences in the biology of the
parasite rather than drug susceptibility per se.
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zoites, intrinsic differences in latency periods of the
inoculated sporozoites (tachyzoites, bradyzoites), and
activation of dormant parasites by external stresses or
seasonal stimuli [141,142]. In bird malarias there is rein-
fection of tissues from blood stage parasites. Following
their seminal discovery of the pre-erythrocytic develop-
mental stage in the liver, Shortt and Garnham initially
suggested that this might also occur in the primate
malarias [59-61]. However there is no convincing evi-
dence to support this theory, and most are now agreed
that reinfection from the blood stage back to the liver to
p r o d u c es e c o n d a r yt i s s u es t a g e sd o e sn o tt a k ep l a c ei n
the primate malarias.
The temperate zone P. vivax usually had an incuba-
tion period of 8-9 months so emergence of an infection
acquired in late summer or autumn could coincide with
vector emergence in the following late spring or sum-
mer. Further south in temperate climes P. vivax infec-
tions had a primary illness two to three weeks after
mosquito inoculation but the first relapse occurred 8-9
months later. Although the interval ("latency”)b e t w e e n
the primary infection and first relapse for this “Mada-
gascar phenotype” was long (8-10 months), the subse-
quent inter-relapse intervals were short (Figure 7). In
fact they were similar to the intervals from primary
infection to early relapse which occurred in some Mada-
gascar/St Elizabeth phenotypes and all Chesson pheno-
types. This observation sits uncomfortably with a simple
preprogrammed biological clock conjecture in which
each sporozoite has a programmed latency. Lysenko et
al pointed out that if the inoculated sporozoites were
indeed a mixture of short and long-latency “zoites” then
long latencies would only be evident if the sporozoite
i n o c u l aw e r ev e r ys m a l l( o t h erwise there would almost
invariably be one or more tachyzoites in the inoculum,
and its emergence and subsequent treatment would
obscure any later emergence of bradyzoites) [140].
Under this conjecture then perhaps failure to relapse
early simply implies that long-latency (bradyzoites) only
were inoculated. Much of the theorizing preceded dis-
covery in 1982 of the dormant or persistent liver stage-
now called the hypnozoite [65-69]. After the discovery
of the hypnozoite the biological clock model was
refined. The generally accepted theory (as described,
and disputed, by Schmidt) has been that “sporozoite
populations of all strains of P. vivax, P. ovale, and relap-
sing simian malarias such as P. cynomolgi, include a sub-
population that completes development promptly and is
responsible for the early primary attack, and a group of
subpopulations that undergo partial development to the
resting hypnozoite stage. Subsets of these dormant pre-
erythrocytic stages are preprogrammed to resume devel-
opment at different times and, via this built-in time
clock, evoke the sequence of relapses that characterize
sporozoite-induced infections with the aforementioned
plasmodia” [82]. As discussed previously it is difficult to
understand how multiple relapses could occur at regular
intervals with generally small inocula (median ~ five
hypnozoites) and a simple clock mechanism. This
remarkable efficiency suggests that some activation or
feedback mechanism must operate in addition. A recent
suggestion is that mosquito bites themselves might pro-
vide the trigger - perhaps by parasite sensing of a mos-
quito protein [143]. This is difficult to reconcile with
the similarity of latency periods in indigenous peoples
living in malaria endemic areas and the latency periods
observed in malaria therapy patients and returned sol-
diers (i.e. away from seasonal mosquitoes and indepen-
dent of season). There are relatively few recent data on
relapse patterns in frequent relapse “tropical” vivax
malaria, but the available evidence confirms the remark-
able periodicity documented in the volunteer studies
with the “Chesson strain”. Most informative are studies
in which anti-malarials such as quinine or the artemisi-
nin derivatives have been used as these drugs are elimi-
nated rapidly and do not suppress or delay the
emergence of subsequent relapse [107,144,145]. Much of
the early volunteer data with tropical “strains” was con-
f o u n d e dp a r t l yb ys l o w l ye l i m i n a t e dd r u ge f f e c t sa n d
inoculations of unnaturally large numbers of sporo-
zoites. Coatney realized this and so, in his classic series
of 204 sporozoite-induced infections with the Chesson
strain [75], he made detailed longitudinal observations
following a single infected mosquito bite (Figure 8). The
number of relapses varied considerably. In the seven
volunteers who were not reinfected the median (range)
number of relapses following a single bite was five (one
to nine) and 11 of the 39 relapses in this group (28%)
occurred more than six months after the initial infec-
tion. The interval from one relapse to the next was
remarkably similar but overall the inter-relapse intervals
gradually lengthened. Importantly there could then be
very long intervals between relapses (four relapses
occurred with preceding latencies exceeding six months.
The maximum documented interval was 397 days). This
proves that long-latency does occur with the tropical
frequent relapse phenotype.
These patterns of relapse are also illustrated well in
the primate model (Figure 9); the Rhesus monkey
infected with P.cynomolgi (the primate malaria “equiva-
lent” of P. vivax) [69]. In Schmidt’s detailed longitudinal
series [82] he noted that “The mean days separating
each of the first four attacks (primary and first three
relapses) were essentially identical in infections treated
with chloroquine in combination with potentially cura-
tive agents, varying from 18.8 to 21.8 days from onset of
patency in infections induced with the smaller inoculum
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lums”. In these monkey experiments where different
sporozoite inocula were evaluated, it was noted that,
although there was no clear difference in the number of
relapses between monkeys inoculated with 5 × 10
2 spor-
ozoites up to 5 × 10
6 sporozoites, “the intervals between
relapses were related to size of inoculum, being dis-
tinctly shorter in monkeys inoculated with 5 × 10
6 spor-
ozoites than in those challenged with 5 × 10
2
sporozoites, with recipients of 5 × 10
4 sporozoites occu-
pying an intermediary position”. Taken together with
the absence of any relapses following an inoculum of
only 5 sporozoites in three monkeys this argues for acti-
vation of a proportion of hypnozoites per relapse, and is
consistent with the earlier observations in soldiers and
malaria therapy patients of a fixed fraction of relapses
following each illness episode in vivax malaria (Figure
16). It is unfortunate that inocula between 5 and 500
sporozoites were not studied in the primate model.
The biology of relapse
Any theory seeking to explain the remarkable biology of
Plasmodium vivax relapse must accommodate the fol-
lowing
1. Relapses show remarkable periodicity.
2. Early relapses reach patency around three weeks
after starting treatment which suggests emergence
from the liver at least one week earlier.
3. Not all P. vivax primary infections are followed by
a relapse. In Thailand approximately 50% of infec-
tions are followed by a subsequent relapse within 28
days if a rapidly eliminated anti-malarial drug (arte-
sunate) is given for treatment of the primary infec-
tion and primaquine is not given [107]. Elsewhere
the probability of relapse generally varies between
20% and 80%. Animal experiments, the malaria ther-
apy experience, and volunteer studies all suggest this
proportion is a function of sporozoite inoculum.
4. Multiple relapses are common, particularly in
young children, even though sporozoite inocula are
thought to be relatively small (median 6-10 sporo-
zoites). It is not uncommon in tropical areas for
children to have four to six relapses at 4-6 week
intervals and sometimes more following an incident
infection. Even larger numbers of relapses were
observed in soldiers following intense exposure and
in Rhesus monkeys receiving very large sporozoite
inocula. Importantly the fraction of people experien-
cing a relapse after each illness episode in a particu-
lar location appears constant
5. In long-latency phenotypes there is commonly a
period of 8-9 months either before the first sympto-
matic infection, or between the first symptomatic
infection and the first relapse. This long-latency
interval appears to be normally distributed (mode 28
weeks for the Madagascar strain [24,25] (Figure 2).
Sometimes there are several short interval relapses
followed by a long interval. Conversely long latencies
may also occur after multiple relapses in the tropical
frequent relapse phenotype [75] (Figure 8).
6. if there are further relapses after the long latent
period then they occur frequently with short inter-
vals which are very similar to those observed in the
tropical “strains”.
7. The relapses in clinical studies conducted in ende-
mic areas are commonly with a genotype which is
different to that identified in the primary infection
(48% in Columbian isolates, 55% in Indian isolates,
61% in Thai and Burmese isolates, and 71% in East
Timor isolates) [146-148].
8. A remarkably high proportion of acute infections
with Plasmodium falciparum are followed by an epi-
sode of P. vivax infection. The proportion is cur-
rently 30% in Thailand [136-138] and 50% in
Myanmar [149]. The intervals between the acute P.
falciparum malaria illness and the subsequent P.
vivax malaria are similar to those between acute P.
vivax m a l a r i aa n dt h es u b s e q u e n tP. vivax relapse.
The epidemiological characteristics suggest that
these are all relapses (Figure 20).
It is also interesting and perhaps relevant that in ende-
mic areas, despite often low seasonal transmission, P.
vivax maintains a high degree of genetic diversity
Relapses of vivax malaria arise from activation of latent
hypnozoites (ALH)
Swellengrebel and de Buck [17] noted that relapse rates
were higher in naturally acquired P. vivax infections (up
to 50%) than in mosquito-borne infections with the
local strains in neurosyphilis patients (despite larger
inocula in the latter). They ascribed this to immunity,
and this was undoubtedly a contributor, but another
explanation is possible. That is that in endemic areas a
high proportion of the population have latent P.
vivax hypnozoites which can be activated by a suffi-
cient stimulus.
Four lines of evidence support this “Activation of
latent hypnozoites” (ALH) hypothesis.
1. Mixed species infections
Mixed blood stage infections with P. falciparum and P.
vivax are underestimated by microscopy, but, even with
sensitive PCR techniques, this proportion is insufficient
to explain the 30% to 50% of patients in SE Asia who
experience vivax malaria following falciparum malaria
[138]. The interval between the primary P. falciparum
infection and the subsequent P. vivax malaria strongly
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ing evidence that these are P. vivax relapses and not
simultaneously acquired infections comes from entomol-
ogy studies in which single anopheline mosquitoes have
been examined for both species [150]. If these mixed spe-
cies infections resulted from simultaneous inoculation
then 30 to 50% of anopheline vectors carrying one spe-
cies should also carry the other. In fact finding vectors
with both P. falciparum and P. vivax sporozoites is rela-
tively uncommon (overall in Asia 6.6% of P. falciparum
sporozoite positive mosquitoes (17 of 258) also contained
P. vivax). In the published literature not one of the 45
individually examined malaria positive wild anopheline
vectors trapped in Thailand contained both malaria spe-
cies [150]. This is also supported by the rarity of finding
patients or healthy subjects with gametocytes of both
species in the blood at the same time. Development rates
in the mosquito are also slightly different (P. vivax being
more rapid). Although space-time clustering of infections
may occur in low transmission areas it is implausible that
over 20% of P. falciparum inoculations would be asso-
ciated with a separate P. vivax inoculation within one or
two days, particularly when individuals receive on aver-
age less than one infectious bite per year. There is other
supporting anecdotal evidence from travellers and from
soldiers with brief periods of exposure in SE Asia. These
groups have much lower rates of P. vivax following P. fal-
ciparum. The most plausible explanation for these find-
ings is that the majority of these P. vivax episodes arise
from hypnozoites which were latent in the liver of the
patient at the time of acquiring P. falciparum (ALH).
The remarkable similarity of both the timing of the P.
vivax recurrences and their variance strongly suggest that
latent P. vivax hypnozoites are activated by acute falci-
parum malaria.
2. Heterologous genotypes
If P. falciparum malaria activates latent P. vivax hypno-
zoites then there is no reason why P. vivax malaria
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Figure 20 The median (IQR, range) Intervals between acute P. falciparum malaria (in green) and acute P. vivax malaria (in red) and the
subsequent vivax malaria episode in patients studied in Thailand following different anti-malarial treatments. The figures in brackets are
the number of patients studied [136-138]. * reinfection excluded.
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rily the finding of heterologous genotypes in one half to
two thirds of P. vivax relapses [146-148]. In these cases
where the original genotype was not detected in the
malaria recurrence then either the inoculated infection
did not relapse, or its hypnozoite(s) were activated but
their progeny were outcompeted by the earlier activation
or more rapid growth of the progeny of the activated
latent hypnozoite(s). In approximately one third of P.
vivax relapses studied in South East Asia, the malaria
parasites isolated are either identical or closely geneti-
cally related to the primary infection. Relatedness could
occur if there is little genetic diversity in the area where
P. vivax malaria was acquired, or could result from
recombination in the anopheline vector with the pro-
duction of genetically related sibling sporozoites (i.e.
simultaneous inoculation). If the “cross” took place sev-
eral cycles of infection previously then subsequent infec-
tions may contain highly related parasites through
successive interbreeding between related siblings. More
work on this important area is needed. However in the
majority of relapses the parasites are clearly genetically
unrelated. In the one third of patients in whom the
relapse is homologous or highly related with the primary
infection, either there were no latent hypnozoites (as in
volunteer studies), or the homologous infection’s hypno-
zoites’ progeny won the race to patency against the het-
erologous hypnozoites’ progeny. It is evident then that
close “races” between different genotypes to reach
patency commonly result in gametocyte genotype mix-
tures in relapses (which may then recombine in the
mosquito). Further support for the ALH hypothesis
comes from observations in mothers and their infants
living in a malaria endemic area on the north-west bor-
der of Thailand. The relapses of vivax malaria in the
babies’ mothers were usually genetically different to
those which caused the primary infection, as in other
patients studied in this area, whereas the relapses which
followed the first P. vivax infection of life in their babies
were usually of the same genotypes as those which
caused the initial infection [151]. Obviously the infants
could not have any previously acquired latent hypno-
zoites in their livers to be activated by the illness.
3. Natural versus artifical infection relapse rates
Higher rates of vivax relapse in indigenous compared
with artificial infection would also be explained by the
ALH hypothesis. The incidence and number of relapses
depends on the number of sporozoites inoculated. If all
relapses derived from the inoculated infection then arti-
ficial infections which follow inoculations with 5-10
times more sporozoites should have higher, not lower
rates of relapse. Relapse rates were particularly high in
soldiers who were immunologically naïve and underwent
intense exposure. If all relapses derived from the most
recent inoculum then there should be no relationship
between intensity of exposure and number of relapses.
4. Long-latency also occurs in the tropical frequent relapse
“Chesson” P. vivax phenotypes
Four of seven volunteers receiving a single infected mos-
quito bite in Coatney’ss e r i e sh a dr e l a p s e so ft h eC h e s -
s o ns t r a i no fP. vivax with variable but long latency
periods - all exceeding six months after their preceding
relapse [75]. It is not uncommon to encounter patients
returning from malaria endemic areas where tropical
phenotypes are prevalent with relapses more than 3
months after either a primary infection or return to the
non-endemic area (of course these might also be long-
latency phenotypes particularly if the interval is eight
-10 months). This proves that some hypnozoites of fre-
quent relapse phenotypes can remain dormant for long
periods.
Mechanisms of hypnozoite activation
If acute malaria activates latent hypnozoites and thereby
causes vivax malaria relapses then it seems that a signifi-
cant systemic illness is necessary for this activation. In
the first half of the twentieth century, it was widely
believed that a variety of external stresses could bring
on a relapse of malaria [140]. By analogy, relapses in the
bird haemosporidian parasite Leukocytozoon are pro-
voked by the stresses of egg laying and the exhaustion
of long migratory flights [152]. It was even taught in
some textbooks of tropical medicine that Cinchona alka-
loids should be given before surgery to pre-empt a
relapse of malaria. However formal studies to provoke
relapses of vivax malaria, which included forced route
marches, simulated altitude, and induced hypoxia, did
not yield convincing results [153,154]. Nevertheless it is
interesting that soldiers in field hospitals in the Mediter-
ranean region between 1940 and 1945 (who had
acquired P. vivax in North Africa or Italy) were appar-
ently considerably more likely to experience vivax
malaria (presumably a relapse) if they had pneumonia or
hepatitis compared with trench foot [155,156]. In our
own series of children seen every day for over 18
months on the Thai-Burmese border during a study of
the SPf66 malaria vaccine [157]P. vivax episodes were
associated with malaria, but not with minor illnesses (S
Lee; personal communication), so it seems that a sub-
stantial systemic stimulus is required.
Periodicity can be generated in several ways in biologi-
cal systems. Illness generally (and the associated cyto-
kine responses) or malaria specifically could provide the
activating or inhibitory necessary stimuli to generate
periodic relapses in vivax malaria. Overall it seems most
likely that the illness associated with the infection
itself is the activator in P. vivax relapses (Figure 21),
and that each symptomatic episode provides an
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relapse. A simple clock mechanism with a single unimo-
dal distribution of latencies alone is inadequate to
explain the observed phenomena. Equally, as explained
previously, a multiplicity of different latencies with a
single harmonic is very complex and difficult to recon-
cile with the efficient use of relatively small sporozoite
inocula (median ~10 sporozoites). For efficient yet peri-
odic activation of small numbers of hypnozoites (i.e. so
that they do not all activate together) it is necessary
either to hypothesise a negative feedback mechanism,
which may occur with illness being the negative feed-
back, or propose simply a relatively broad temporal dis-
tribution of latencies (analogous to seeds germinating or
eggs hatching), and a low individual susceptibility to
activation. Either results in several relapses at regular
intervals, each activated by the preceding illness. Impor-
tantly the proportion of susceptible hypnozoites acti-
vated would be fractional, at least initially, which fits
with the observed fixed proportions of patients who
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Figure 21 Proposed mechanism and sequence of Plasmodium vivax relapse activation in a malaria endemic area.I na ni l l u s t r a t e d
example, at the time of infection (sporozoite inoculation) the individual already has hypnozoites of two different genotypes acquired from two
previous inoculations which are latent in the liver. The different genotypes are denoted by different colours (red and white). Half the newly
acquired infection sporozoites (blue) develop into preerythrocytic schizonts and half become dormant as hypnozoites (the estimated proportions
for tropical “strains”) [59,69]. Illness associated with the blood stage infection activates a small fraction of the hypnozoites (inset shows a “classic”
P. vivax fever pattern in relation to asexual parasite development). In this example there is one hypnozoite of each genotype and each is
activated by the illness and each develops into a pre-erythrocytic schizonts. By chance the progeny of one of the preexisting latent hypnozoites
reach pyrogenic densities before the progeny of the recently inoculated hypnozoite (inset shows the logarithmic growth of the three
genotypically different infections-vertical axis shows number of parasites in the body). The consequent febrile illness then suppresses further
multiplication of the blood stage infection so that the progeny of the other two prerythrocytic schizonts may not reach transmissible densities.
The ensuing illness activates some of the remaining hypnozoites (the same fraction as were activated initially) and relapses continue until either
the number of hypnozoites is exhausted or some fail to be activated. If there are some hypnozoites which fail to be activated these may be
activated at a later date by a subsequent malaria infection.
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leave a significant proportion of unactivated (but activa-
table) hypnozoites which remain latent until either they
die (for example when the host hepatocyte dies) or they
are activated by a systemic il l n e s ss u c ha sm a l a r i a .T h i s
would explain the high rate of vivax malaria (presum-
ably relapses) following falciparum malaria. It follows
that the number of immediate relapses per mosquito
inoculation will decrease with increasing age in endemic
areas, as the stimulus to hypnozoite activation declines
with increasing disease controlling immunity, and
immunity increases the probability that the relapse is
asymptomatic. In this respect it is interesting that in
Thailand the incidence of symptomatic P. vivax peaks in
childhood [106], but P. vivax malaria following P. falci-
parum malaria shows a weaker age relationship. P. falci-
parum may contribute significantly to P.vivax
transmission, particularly in young adults, through this
mechanism. It also follows that with small inocula it is
quite possible for all sporozoites to develop immediately
(early infection, no relapses) or for all to result in hyp-
nozoites, and all the hypnozoites to become latent (no
early infection, first infection follows activation stimulus
such as a malaria illness).
For temperate strains of P. vivax, as suggested by sev-
eral investigators previously, there are clearly at least
two populations of hypnozoites, one becoming activata-
ble early (as for tropical P. vivax) and another remaining
latent and not immediately activatable. The study of
Cooper et al, in which blood induced homologous (St
Elizabeth strain) infections were induced 120 days after
infectious mosquito bites, is informative in this respect
[35]. The blood inoculations reliably gave rise to symp-
tomatic malaria but critically did not affect the timing of
the subsequent relapse. This suggests that the hypno-
zoites (half way through their sleep) were absolutely
refractory at this time. It is likely that once hypnozoites
do become activatable, that there is a background rela-
tively low rate of spontaneous activation in order to
account for the distribution of latencies. Thus for the
long-latency P. vivax the first relapse after the long
latent period is usually spontaneous, but the illness then
activates further hypnozoites, accounting for the subse-
quent short inter-relapse intervals. If this is correct it
follows that first relapses which occur with a long-
latency interval (i.e. 8-10 months after the primary
infection) should usually be of a similar genotype to the
initial infection, whereas relapses at other times could
be heterologous. If there are subsequent relapses i.e.
which follow the first relapse after the latent period (i.e.
with a short periodicity) then these could be genetically
heterologous.
Plasmodium vivax in temperate zones has clearly
evolved to adapt to the long winters across the Northern
hemisphere [17,19,27-29,79,158]. It is interesting to
speculate that the large proportion of sporozoites dedi-
cated to latency, and the relatively low number of
relapses compared with the tropical strains may reflect
the high natural wastage of hypnozoites in hepatocytes
which die before the hypnozoites become activatable. In
experimental P. cynomolgi bastianelli infection in the
Rhesus monkey Garnham observed a ten-fold reduction
in the number of hypnozoites in serial liver biopsies
over a nine month period, but it is not clear how much
of this reduction resulted from activation and how
much was from cell death [68].
The hypnozoite can be considered as an unactivated
sporozoite. If the duration of pre-erythrocytic develop-
ment of the liver stage is similar for sporozoites and
hypnozoites, as seems likely, this puts activation at the
time or shortly after presentation with acute malaria (of
any species). If the ALH hypothesis is correct then the
key biological difference between frequent relapse and
long-latency P. vivax phenotypes lies in the temporal
distribution of susceptibility to activation among the
sporozoites. This can then be subdivided into the pro-
portion of sporozoites which activate immediately and
the subsequent temporal distribution of susceptibility to
activation among the remaining hypnozoites. The
genetic basis for this regulation may be difficult to find,
as it could well reflect subtle quantitative rather qualita-
tive differences. Recent studies in murine malaria indi-
cate a central role for iron sequestration in controlling
pre-erythrocytic development through malaria illness
induction of the iron regulatory hormone hepcidin
[159,160]. It is possible that iron availability also plays
an important regulatory role in controlling hypnozoite
activation and pre-erythrocytic development. One possi-
ble mechanism contributing to regular short interval
(three weeks) relapses is a malaria illness related tem-
porary halt to liver-stage development (mediated by
reduced iron availability), which is then lifted with clini-
cal recovery. Some of these hypotheses may be testable
in the ex-vivo hepatocyte culture systems [70].
In summary this ALH hypothesis proposes that there
is indeed a biological clock (which is most evident in
temperate strains) determining latency in Plasmodium
vivax. This clock (which could be an intrinsic parasite
clock, or could reflect a host-parasite interaction) deter-
mines the length of the interval before the hypnozoite
becomes susceptible to activation, but that there is a
separate sensing mechanism which determines whether
or not activation does occur. The trigger could be either
a positive activation stimulus or removal of inhibition.
This mechanism may activate spontaneously once the
hypnozoite has become susceptible, and spontaneous
activation presumably usually explains the first relapse
after a long latent period, but once susceptible activation
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such as malaria. Activation must involve signaling via
the infected hepatocyte (which is very sensitive to sys-
temic inflammatory responses). Importantly the indivi-
dual probability of activation for each hypnozoite is low,
allowing accumulation of latent but “activatable” hypno-
zoites after each sporozoite inoculum. This implies that
people living in vivax endemic areas commonly harbour
latent but “activatable” hypnozoites. In endemic areas of
South-East Asia, if patients who acquire falciparum
malaria are representative of the population, this figure
is approximately one quarter to one third. The periodi-
city of P. vivax relapses is derived from the sequential
activation of hypnozoites by illness. Mathematical mod-
eling will provide valuable insights into which activa-
tion-inhibition model best fits the observed malaria
therapy, volunteer, and epidemiological information.
Implications for epidemiological assessment
If the ALH theory is correct it also explains why relapse
phenotypes in tropical malaria endemic areas may be
difficult to characterize, and why in areas with long-
latency P. vivax frequent relapse patterns may still be
observed (Figure 22). This is because a primary illness
with long-latency P. vivax of the “Madagascar” or “St
Elizabeth” phenotype may activate previously acquired
latent hypnozoites (of similar phenotype) -giving an
early relapse. The illness caused by the relapse could
then activate further latent homologous or heterologous
hypnozoites. Thus several relapses may follow at short
intervals even though all the parasites are of the long-
latency type. The net result would be indistinguishable
from the epidemiological pattern of frequent relapse
vivax malaria (Figure 22). The converse -long-latency
with the tropical frequent relapse phenotypes was
demonstrated clearly in the studies of Robert Coatney
and his colleagues [75]. If both types are prevalent in
the same area then identifying phenotypes from illness
patterns becomes even more difficult, and it may be
i m p o s s i b l et od i s c e r nt h el o n g - l a t e n c yp h e n o t y p e s
amongst the frequent relapses. In temperate areas, such
as Southern Europe, the early spring-summer wave of
vivax malaria which preceded the appearance of anophe-
line vectors was an obvious clue, but in tropical regions
with longer transmission seasons this may be difficult to
discern [19]. The presence of long-latency phenotypes
m a yo n l yb ee v i d e n ti nt r a v e l l e r sa n ds o l d i e r sw h o
spend a brief period in the endemic area, do not receive
primaquine, and then return to a non-endemic area and
relapse many months later without re-exposure
[108-112]. These cases provide an important epidemio-
logical signal. There is uncertainty over the true epide-
miology of relapse patterns over a large proportion of
the P. vivax endemic world. Despite a resurgence of
interest in malaria, and the belated recognition of the
importance of Plasmodium vivax,t h i sl a r g ek n o w l e d g e
gap seems to have gone unnoticed. It is quite possible
that long-latency phenotypes are present in many tropi-
cal areas (Figure 17). Defining these patterns is an
essential prerequisite for therapeutic assessments, con-
trol and elimination planning, and the evaluation of
novel interventions such as vaccines.
Implications for the emergence of anti-malarial drug
resistance
The factors determining de-novo selection of anti-
malarial drug resistance are likely to be similar across all
malaria parasites (pattern of drug exposure, parasite bio-
mass, frequency and stability of the genetic or epigenetic
mechanism, fitness cost) [161]. The much lower parasite
biomass in P. vivax malaria makes de-novo selection
less likely than in P. falciparum infections, some of
which may comprise very large numbers of parasites (>
10
12) [162]. In malaria, recrudescence is necessary for
onward transmission of a de-novo resistant mutant
parasites’ progeny [161]. In P. vivax malaria the de-novo
recrudescent infection is effectively in a race with the
relapse-either of heterologous or drug sensitive homolo-
gous (sibling) parasites. Resistant parasites will only be
transmitted if their progeny reach transmissible parasite
densities before the relapse does. If the de-novo resis-
tance is high grade then the resistant parasites may
expand in numbers rapidly and may not be impeded by
the relapse. However if the first step in resistance is a
small reduction in susceptibility, as is more usual in
anti-malarial drug resistance, then resistance cannot be
transmitted onward in infections in which the relapse
becomes patent before the recrudescence would have
(Figure 23). This is because parasite multiplication falls
rapidly once symptoms have developed, and treatment
usually follows soon afterwards. Of course the resistant
parasites are less drug-sensitive so they will have a “sec-
ond chance” to recrudesce later if the same drug is used
for treatment of relapse, but treatment may change, pri-
maquine may be added, and immune responses are
strengthening -all of which reduce the chance of subse-
quent recrudescence. The relapse therefore pre-empts
the expanding intra-host population of de-novo resistant
parasites. Together with the lower biomass, and the use
of primaquine in “combination therapies”,t h i sm a y
explain the slower emergence of low-grade anti-malarial
drug resistance in P. vivax compared with P. falciparum.
Slowly eliminated drugs interefere with the resistance
protection provided by relapse. Chloroquine has a slow
multiphasic elimination phase and suppresses the
relapse of sensitive parasites for approximately two
weeks (from two to six weeks). Mefloquine has a differ-
ent profile of elimination, and provides longer
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reduce potential interference with resistance emergence
by relapse providing greater suppression of the sensitive
compared with the resistant parasites and they therefore
reduce the delay on resistance emergence. In summary
early relapse provides a brake on the emergence and
spread of low-grade resistance in Plasmodium vivax by
pre-empting recrudescence.
Implications for genetic diversity
Activation of hypnozoites from different preceding
inoculations will commonly result in two or more geno-
types reaching patent parasitaemia at similar times. As
gametocytogenesis in P. vivax occurs simultaneously
with asexual stage development this provides an effec-
tive method of increasing the likelihood that a mosquito
will ingest gametocytes of different genotypes, thereby
facilitating meiotic recombination between genetically
unrelated P. vivax parasites. This must be an important
contributor to the relatively high degree of genetic
diversity in P. vivax often found in areas with very low
seasonal transmission.
Practical implications
If the ALH theory is correct then the epidemiology of
malaria relapse and the biology of interaction between
the species need reconsideration. If long-latency Plasmo-
dium vivax still contributes a significant proportion of
vivax malaria in the Indian sub-continent and further
west then current methods of assessing drugs and vac-
cines may also need reconsideration (Table 3).
Radical treatment therapeutics
In therapeutic assessments a follow-up period of six
months or less may miss a significant proportion of the
Newinfection Relapses Tropicalfrequentrelapsephenotype
0123456789
Months
NewinfectionRelapses
Longlatencyrelapsephenotype
Previously
acquired
hypnozoites
Figure 22 Potential similarity of relapse patterns with the long-latency and frequent relapse P. vivax phenotypes. The different colours
and symbols represent different genotypes in two hypothetical infections. The upper panel shows the relapse pattern where the frequent
relapse phenotypes are prevalent. The patient has hypnozoites from three preceding inoculations present at the time of illness from the newly
acquired (red) infection. These are sequentially activated as proposed in Figure 21. Three relapses occur with similar periodicities, and a later
randomly activated relapse occurs 8 months later. In the lower panel the long-latency phenotypes are present. Activation occurs as above and
the long-latency relapse emerges nine months later. The initial relapse patterns associated with the two different phenotypes are identical. This
illustrates the difficulty in excluding the presence of long-latency phenotypes in malaria endemic areas.
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derive from heterologous latent hypnozoites then
malaria control interventions which are effective will not
prevent relapses emerging for months or years, although
their number will reduce as the reduced transmission
will result in less illness and therefore less hypnozoite
activation. Mass drug administration with radical cura-
tive regimens (currently primaquine is the only option)
would be the only way to eliminate this reservoir of
infection quickly. Epidemiological assessments in older
children and adults in endemic areas may underestimate
the burden of vivax malaria as partial immunity (and
premunition) will ameliorate disease severity and may
lead to reduced activation of relapses. This would result
in relatively low relapse rates. The proportion of acute
falciparum malaria infections, which are followed by P.
vivax m a yb eab e t t e ri n d i c a t o ro ft h ep r e v a l e n c eo f
latent hypnozoite carriage.
It is possible that much of the variance in responses to
primaquine is explained by differences in rates and bur-
dens of latent hypnozoite carriage and degree of immu-
nity and not variation in drug susceptibility. The same
factors which affect therapeutic responses in the blood
stage infection appear to affect the responses to hypno-
zoitocidal treatment i.e. organism load and immunity.
We have tended to consider 8-aminoquinoline efficacy
only from the perspective of the drug, and we do not
take into account either organism load, organism phe-
notype, or host immunity. Taking a quantitative
approach to assessing 8-aminoquinoline radical curative
activity based on hypnozoite burdens may be a valuable
approach. Patients with very large liver burdens of hyp-
nozoites from either a very heavy inoculation or multi-
ple inoculations and little or no immunity (such as
soldiers) would be expected to have a larger number of
relapses than travellers who have a brief period of expo-
sure. Studies of radical curative activity in soldiers may
not be comparable to studies in travelers. Studies in
adults may not be comparable to studies in children.
The apparent radical curative activity of primaquine
would be expected to improve as malaria transmission
falls. Lower dose regimens may have useful efficacy in
this context. Long term follow up (minimum one year)
of well characterized patients with parasite genotyping
in low transmission settingss h o u l dh e l pt od i s s e c tt h e
contributions of pre-existing versus recently inoculated
0
Total parasites
Weeks
2 4 3 1
1010
108
106
104
102
1
Relapse
Figure 23 Relapse pre-empts the emergence of de-novo anti-
malarial drug resistance. De-novo drug resistance is a rare event
and usually there is only one mutant resistant parasite which
multiplies while the sibling drug sensitive parasite population
declines (green) [160]. Only a highly resistant parasites’ progeny (red
line) can reach transmissible densities in blood (total numbers circa
100,000,000 in the body) before the relapse (comprising drug
sensitive parasites) becomes patent and the consequent illness (and
any treatment effect) suppresses multiplication. Slowly eliminated
anti-malarial drugs reduce this protective effect by reducing
multiplication of the relapse parasites more than multiplication of
the de-novo resistant parasites.
Table 3 Epidemiological implications
1. A substantial proportion of the population in P. vivax endemic areas harbours latent but activatable hypnozoites. Some of these may derive from
inoculations which were not followed by any illness.
2. If relapse rates exceed 50%, then relapse becomes the predominant cause of vivax malaria.
3. Spontaneous or activated relapse followed by asymptomatic parasitaemia may be an important source of P. vivax transmission.
4. Reducing P. vivax transmission will have a smaller than currently predicted effect on the incidence and prevalence of vivax malaria initially.
5. Reducing P.falciparum transmission may reduce the incidence of P.vivax infections and reduce P.vivax transmission. However any effect on the
incidence of clinical disease would probably be delayed because reducing falciparum malaria will also reveal vivax malaria by lifting suppression
in mixed infections, and a reduction in vivax incidence will reduce immunity. A single radical treatment for all malaria infections may be justified
in areas where both parasites are prevalent (i.e. ACT + radical primaquine regimen) [143].
6. It is very difficult to exclude the presence of long-latency P. vivax phenotypes in studies conducted in vivax endemic areas. Long-latency
phenotypes may be prevalent over a much wider area of the tropics than currently thought.
7. Assessment of the efficacy of interventions requires characterization of the prevalent relapse phenotypes.
8. Assessments of radical curative activity where long-latency phenotypes are prevalent require one year’s follow-up. Genotyping should assist in
assessing long-latency relapse.
9. The proportion of genotypically different (heterologous) relapses will fall as transmission intensity falls
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entomology and genotyping studies in wild-trapped ano-
pheline vectors to determine mixed genotype and
genetic recombination rates.
Immunity
It is interesting to speculate on the role of relapse in
enhancing the opportunities for recombination and how,
in the pre-anti-malarial era, relapse would have contrib-
uted to persistence of the untreated infection. Rechal-
lenge experiments showed that a “strain specific”
immunity developed after protracted symptomatic infec-
tion with that P. vivax strain. But this did not always
prevent subsequent parasitaemia, particularly if rechal-
lenge was many years later [163]. Despite considerable
investment in a P. vivax vaccine there is relatively little
information how immunity to vivax malaria is acquired
and maintained in the context of frequent infection and
relapse with different genotypes [164]. It is generally
recognized that asymptomatic P. vivax infections are
common in endemic areas but their overall contribution
to P. vivax transmission in malaria-endemic areas, and
the importance of relapse in maintaining these asympto-
matic infections has not been characterized adequately.
However the malaria therapy experience suggested that
asymptomatic infections were a very important source
of infection [163]. An effective vaccine which did not
confer long-lasting immunity and required frequent
boosting might provide a selective pressure towards
longer latency.
There are major questions about the basic biology and
the epidemiology of Plasmodium vivax relapse which
first need recognizing, and then need answering, if we
are to address seriously controlling and eliminating this
important malaria parasite [165].
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